日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial

在中国晚期胰腺腺癌患者中,NALIRIFOX 对比吉西他滨联合白蛋白紫杉醇:一项随机、开放标签的 II 期试验

Gao, Chuntao; Zhang, Yanqiao; Qu, Xiujuan; Chen, Xingyun; Zhang, Jingdong; Wu, Heshui; Sun, Meili; Zha, Yong; Wang, Junbin; Wang, Yusheng; Li, Zhihua; Gao, Jinghua; Lin, Rongbo; Zang, Aimin; Zhang, Huiqing; Yuan, Xianglin; Du, Chengyou; Zhao, Jun; Yang, Yongsheng; Shi, Xuetao; Cheng, Wei; Wang, Bangmao; Wu, Shikai; Zhao, Tiansuo; Wang, Jian; Gao, Song; Wang, Xiuchao; Ma, Weidong; Liu, Rui; Shi, Yehui; Liu, Yanping; Xie, Yijiao; Niu, Miao; Zhao, Fuchen; Yu, Jun; Hao, Jihui

Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study

CDK4/6抑制剂联合内分泌治疗在HR阳性、HER2阴性转移性乳腺癌中的疗效比较:inspiration 01研究

Jia, Yan; Zhang, Jie; Wang, Xu; Hao, Chunfang; Wang, Chen; Li, Shufen; Lu, Ning; Dong, Guolei; Zhao, Weipeng; Jia, Yongsheng; Huang, Libin; Gu, Jiangtao; Shi, Yehui; Tong, Zhongsheng

Mask-Aware Spatiotemporal Classification of Millimeter-Wave Radar Point Cloud Sequences Using DGCNN and Transformer for Child-Pet Recognition in Enclosed Spaces

基于DGCNN和Transformer的毫米波雷达点云序列掩码感知时空分类,用于封闭空间内儿童-宠物识别

Shi, Yehui; Shi, Jianhong

Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

HA121-28 在晚期实体瘤和 RET 融合阳性非小细胞肺癌患者中的安全性、药代动力学和疗效:一项多中心、开放标签、单臂 1/2 期试验

Ruan, Dan-Yun; Huang, Wen-Wen; Li, Yongsheng; Zhao, Yanqiu; Shi, Yehui; Jia, Yuming; Cang, Shundong; Zhang, Wei; Shi, Jianhua; Chen, Jun; Lin, Jie; Liu, Yunpeng; Xu, Jianming; Ouyang, Weiwei; Fang, Jian; Zhuang, Wu; Liu, Caigang; Bu, Qing; Li, Manxiang; Meng, Xiangjiao; Sun, Meili; Yang, Nong; Dong, Xiaorong; Pan, Yueyin; Li, Xingya; Qu, Xiujuan; Zhang, Tongmei; Yuan, Xianglin; Hu, Sheng; Guo, Wei; Li, Yalun; Li, Shengqing; Liu, Dongying; Song, Feixue; Tan, Liping; Yu, Yan; Yu, Xinmin; Zang, Aimin; Sun, Chang; Zhang, Qian; Zou, Kai; Dan, Mo; Xu, Rui-Hua; Zhao, Hongyun

BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study

BEBT-209,一种选择性 CDK4 抑制剂,用于治疗 HR+/HER2- 晚期乳腺癌(BECTOP1):一项 1 期、多中心、开放标签研究

Hu, Zhe-Yu; Jiang, Kegang; Tian, Can; Zhang, Fan; Shi, Yehui; Wang, Ying; Li, Wei; Wu, Biao; Ding, Boni; Liu, Liping; Xiao, Huawu; Yang, Xiaohong; Li, Jing; Xie, Ning; Liu, Binliang; Wang, Shouman; Ouyang, Quchang

DNAJC24 suppresses breast cancer malignancy and serves as a prognostic biomarker.

DNAJC24抑制乳腺癌恶性进展,可作为预后生物标志物

Meng Wenjing, Liu Wei, Yang Yulong, Wang Xiaorui, Zhan Linlin, Luo Yi, Chen Liwei, Wang Yu, Li Guangtao, Shi Yehui, He Yuchao, Tong Zhongsheng, Guo Hua

The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity

CDK4/6抑制剂对肿瘤免疫的双重作用

Si, Yiran; Li, Hongli; Shi, Yehui

Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study

吡咯替尼联合节拍式长春瑞滨治疗曲妥珠单抗治疗失败的HER2阳性晚期乳腺癌(PROVE):一项前瞻性II期研究

Hao, Chunfang; Wang, Xu; Shi, Yehui; Tong, Zhongsheng; Li, Shufen; Liu, Xiaodong; Zhang, Lan; Zhang, Jie; Meng, Wenjing; Zhang, Li

Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors

ESG401(一种Trop2抗体药物偶联物)治疗局部晚期/转移性实体瘤患者的1a期研究

Wang, Jiani; Tong, Zhongsheng; Tan, Yinuo; Shi, Yehui; Wu, Yun; Zhou, Qing; Xing, Xiaoyan; Chen, Xiaomei; Qiu, Fuming; Ma, Fei

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors

DP303c(一种靶向HER2的抗体药物偶联物)在HER2阳性实体瘤患者中的首次人体研究

Zhang, Jian; Du, Yiqun; Meng, Yanchun; Liu, Xiaojun; Mu, Yuxin; Liu, Yunpeng; Shi, Yehui; Wang, Jufeng; Zang, Aimin; Gu, Shanzhi; Liu, Tianshu; Zhou, Huan; Guo, Hongqian; Xiang, Silong; Zhang, Xialu; Wu, Suqiong; Qi, Huanhuan; Li, Mengke; Hu, Xichun